NASDAQ:MEDPMedpace Stock Price, Forecast & News

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MEDP stock has increased by 10.2% and is now trading at $92.18. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medpace.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, July 27th 2020. View our earnings forecast for Medpace.

Medpace will be holding an earnings conference call on Monday, July 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medpace Holdings Inc (NASDAQ:MEDP) announced its quarterly earnings results on Tuesday, April, 28th. The company reported $0.76 EPS for the quarter, missing the consensus estimate of $0.77 by $0.01. The firm earned $230.88 million during the quarter, compared to analyst estimates of $226.23 million. Medpace had a net margin of 12.37% and a return on equity of 16.96%. Medpace's quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.64 EPS. View Medpace's earnings history.

Medpace issued an update on its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of 3.24-3.34 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.28. The company issued revenue guidance of $975M - 1.005 billion, compared to the consensus revenue estimate of $977.76 million.

5 Wall Street analysts have issued 1 year price objectives for Medpace's shares. Their forecasts range from $75.00 to $99.00. On average, they expect Medpace's stock price to reach $86.50 in the next twelve months. This suggests that the stock has a possible downside of 6.2%. View analysts' price targets for Medpace.

Headlines about MEDP stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medpace earned a news sentiment score of 0.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutMedpace.

Some companies that are related to Medpace include EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), PRA Health Sciences (PRAH), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Baidu (BIDU), Alibaba Group (BABA), Square (SQ), JD.Com (JD), Trade Desk (TTD), Adobe (ADBE), Alteryx (AYX) and Cisco Systems (CSCO).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (12.64%), Wasatch Advisors Inc. (6.48%), Pendal Group Ltd (3.09%), State Street Corp (2.43%), Fuller & Thaler Asset Management Inc. (2.05%) and Invesco Ltd. (1.60%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Federated Hermes Inc., Pendal Group Ltd, BlackRock Inc., MERIAN GLOBAL INVESTORS UK Ltd, and Acadian Asset Management LLC. Company insiders that have sold Medpace company stock in the last year include Jesse J Geiger, and Stephen P Ewald. View insider buying and selling activity for Medpace.

MEDP stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Fuller & Thaler Asset Management Inc., Matarin Capital Management LLC, Franklin Resources Inc., Ranger Investment Management L.P., Meritage Portfolio Management, State Street Corp, and Eagle Asset Management Inc.. View insider buying and selling activity for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $92.18.

Medpace has a market capitalization of $3.26 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]